Triple-negative breast cancer (TNBC) is the most aggressive subtype of breast cancer,
which is characterized by the absence of estrogen receptor (ER) and progesterone receptor …

While the outcomes for patients diagnosed with hormone receptor positive (HR+) and/or
human epidermal growth factor receptor 2-positive (HER2+) breast cancers have continued …

Triple-negative breast cancer (TNBC) is characterized by a lack of expression of estrogen
receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 …

Triple-negative breast cancer (TNBC), a highly aggressive subtype of breast cancer,
negatively expresses estrogen receptor, progesterone receptor, and the human epidermal …

Purpose of review Triple negative breast cancer (TNBC) accounts for approximately 10–
15% of all breast cancers and it is associated with a poor prognosis. However, recent new …

Triple-negative breast cancer (TNBC) is a heterogeneous disease comprised of several
biologically distinct subtypes. However, treatment is currently mainly relying on …

Triple negative breast cancer (TNBC) is a heterogeneous group of breast cancers
characterized by their lack of estrogen receptors, progesterone receptors, and the HER2 …

Triple negative breast cancer (TNBC) constitutes the most aggressive molecular subtype
among breast tumors. Despite progress on the underlying tumor biology, clinical outcomes …

Triple-negative breast cancer (TNBC) is a heterogeneous subtype of breast cancer that is
defined by negative estrogen receptor (ER), progesterone receptor (PR) and human …

Simple Summary Triple negative breast cancer (TNBC) represents 15 to 20% of all breast
cancers in the United States. The main treatment option remains chemotherapy, despite …